Instem – argues new project “highlights the strength of our product suite”, what about the recent profit warning?
By Steve Moore | Tuesday 3 May 2022
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Life sciences market IT provider Instem (INS) has announced grant funding for involvement in a research project, emphasising it “highlights the strength of our product suite, which supports the continued global demand for reliable alternatives to traditional testing methods - with industry and regulators alike increasingly recognizing the huge benefits of computational toxicology approaches”...
You must be a registered member to read this story
ShareProphets is reader-supported journalism
Join us for free and gain access to three articles per month
Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.